Neurocrine reports positive Phase 2 schizophrenia study results

Neurocrine Biosciences (NBIX) announced positive Phase 2 trial results for NBI-1117568, an investigational drug for schizophrenia, demonstrating statistically significant symptom improvement at the 20mg dosage. The company has initiated a Phase 3 registrational program based on these findings, with analysts revising earnings estimates upward despite a relatively high P/E ratio of 40.5, suggesting the company may be undervalued. Separately, Neurocrine reported positive data for CRENESSITY™ in pediatric patients and INGREZZA® in tardive dyskinesia, leading UBS to raise its price target to $152, citing confidence in Ingrezza’s growth and the upcoming Crenessity launch.

Analysis

Neurocrine Biosciences (NASDAQ:NBIX) has announced positive Phase 2 clinical trial results for its investigational schizophrenia drug, NBI-1117568, where the 20 mg once-daily dosage led to statistically significant improvements in symptoms as early as Week 3, measured by the Positive and Negative Syndrome Scale (PANSS), with benefits persisting through Week 6, and on the Clinical Global Impression of Severity (CGI-S) scale from Week 2. NBI-1117568 is notably the sole investigational oral muscarinic M4 selective orthosteric agonist in clinical development for schizophrenia, potentially addressing a significant unmet need given the problematic health impacts of current treatments. Following these findings, which included good tolerability with somnolence and dizziness as the most common adverse events and no significant weight gain, Neurocrine has initiated a Phase 3 registrational program. The company's financial health supports these R&D efforts, with 22% revenue growth over the past year, a current ratio of 3.13, and an InvestingPro "GREAT" overall score. While NBIX trades at a P/E ratio of 40.5, InvestingPro analysis suggests undervaluation based on its Fair Value model, a sentiment supported by eight analysts recently revising earnings estimates upward. Additional positive developments include Phase 3 data for CRENESSITY™ showing effective glucocorticoid dose reduction in pediatric congenital adrenal hyperplasia, and Phase 4 data for INGREZZA® indicating improved quality of life for tardive dyskinesia patients. Analyst firms like UBS (PT $152, Buy), Cantor Fitzgerald (PT $170, Overweight), and Stifel (PT $166, Buy) have reiterated positive stances, citing Ingrezza's growth, the upcoming Crenessity launch, and pipeline optimism.

Key Decisions for Investors

• Given the positive Phase 2 results for NBI-1117568 and strong financial health, investors could consider the potential for significant upside if Phase 3 trials are successful, especially considering the drug's novel mechanism for schizophrenia.
• Monitor upcoming catalysts, including the NBI-1117568 Phase 3 data readout and the commercial launch and sales trajectory of CRENESSITY™, as these will be critical in validating the company's growth narrative and pipeline value.
• Evaluate the current valuation (P/E of 40.5) against the backdrop of strong revenue growth (22% YoY), upward analyst earnings revisions, and InvestingPro's Fair Value model suggesting undervaluation, while remaining cognizant of clinical development risks and competitive pressures.